New combo radiation aims to cut prostate cancer treatment time

NCT ID NCT06591819

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a new, shorter radiation plan for men with high-risk or unfavorable intermediate-risk prostate cancer. Participants receive a brachytherapy boost followed by just 5 sessions of whole-pelvis proton therapy. The main goal is to see if this approach is safe, with fewer than 10% of patients experiencing severe urinary or bowel side effects. The study will also track quality of life changes using surveys.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proton therapy and brachytherapy (radiation)
What this could lead to: If successful, this could offer a shorter, more convenient radiation schedule for high-risk prostate cancer with fewer severe side effects.
What could go wrong: This is a small, early-phase trial (30 people) focused on safety, not yet proven to work better than standard treatments. There is still a risk of side effects like urinary or bowel problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.